PL1591109T3 - Preparat zawierający inhibitor deacetylazy histonów wykazujący dwufazowe uwalnianie” - Google Patents
Preparat zawierający inhibitor deacetylazy histonów wykazujący dwufazowe uwalnianie”Info
- Publication number
- PL1591109T3 PL1591109T3 PL04010333T PL04010333T PL1591109T3 PL 1591109 T3 PL1591109 T3 PL 1591109T3 PL 04010333 T PL04010333 T PL 04010333T PL 04010333 T PL04010333 T PL 04010333T PL 1591109 T3 PL1591109 T3 PL 1591109T3
- Authority
- PL
- Poland
- Prior art keywords
- formulation
- profile
- galenics
- induction
- hyperacetylation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000001747 exhibiting effect Effects 0.000 title abstract 2
- 230000002051 biphasic effect Effects 0.000 title 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 title 1
- 102000003964 Histone deacetylase Human genes 0.000 abstract 2
- 108090000353 Histone deacetylase Proteins 0.000 abstract 2
- 108010033040 Histones Proteins 0.000 abstract 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000006698 induction Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000006947 Histones Human genes 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 229960000604 valproic acid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04010333A EP1591109B1 (en) | 2004-04-30 | 2004-04-30 | Formulation comprising histone deacetylase inhibitor exhibiting biphasic release |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1591109T3 true PL1591109T3 (pl) | 2008-11-28 |
Family
ID=34924816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04010333T PL1591109T3 (pl) | 2004-04-30 | 2004-04-30 | Preparat zawierający inhibitor deacetylazy histonów wykazujący dwufazowe uwalnianie” |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20070232528A1 (pl) |
| EP (1) | EP1591109B1 (pl) |
| JP (1) | JP4789927B2 (pl) |
| CN (1) | CN1980647B (pl) |
| AT (1) | ATE399539T1 (pl) |
| AU (1) | AU2005237251B2 (pl) |
| BR (1) | BRPI0509340A (pl) |
| CA (1) | CA2564877A1 (pl) |
| CY (1) | CY1108301T1 (pl) |
| DE (1) | DE602004014723D1 (pl) |
| DK (1) | DK1591109T3 (pl) |
| ES (1) | ES2308065T3 (pl) |
| MX (1) | MXPA06012568A (pl) |
| NZ (1) | NZ550879A (pl) |
| PL (1) | PL1591109T3 (pl) |
| PT (1) | PT1591109E (pl) |
| SI (1) | SI1591109T1 (pl) |
| WO (1) | WO2005105055A1 (pl) |
| ZA (1) | ZA200608714B (pl) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999040883A2 (en) | 1998-02-11 | 1999-08-19 | Faller Douglas V | Compositions and methods for the treatment of cystic fibrosis |
| EP2500063A1 (en) | 2005-02-03 | 2012-09-19 | TopoTarget UK Limited | Combination therapy using HDAC inhibitors and melphalan for treating cancer |
| ES2540204T3 (es) | 2005-05-13 | 2015-07-09 | Topotarget Uk Limited | Formulaciones farmacéuticas de inhibidores de la HDAC |
| CN101282718A (zh) * | 2005-08-10 | 2008-10-08 | 诺瓦提斯公司 | 脱乙酰酶抑制剂的使用方法 |
| EP1957056A2 (en) * | 2005-11-10 | 2008-08-20 | TopoTarget UK Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent |
| BRPI0520686A2 (pt) * | 2005-11-16 | 2009-05-19 | Univ Mexico Nacional Autonoma | uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer |
| US20070207950A1 (en) * | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
| DE102006006532B4 (de) * | 2006-02-10 | 2007-11-08 | Biogenerics Pharma Gmbh | Pharmazeutische Zubereitung |
| EP1839656A1 (en) * | 2006-03-31 | 2007-10-03 | TopoTarget Germany AG | Use of valproic acid for the topical treatment of mild to moderate acne vulgaris |
| CA2649877A1 (en) | 2006-04-24 | 2007-12-21 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
| WO2007146730A2 (en) | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
| EP2056808A4 (en) * | 2006-08-28 | 2009-12-23 | Univ California | SMALL MOLECULAR AMPLIFIER OF HORMONTHERAPY FOR BREAST CANCER |
| US8088951B2 (en) * | 2006-11-30 | 2012-01-03 | Massachusetts Institute Of Technology | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss |
| JP4887427B2 (ja) * | 2006-12-06 | 2012-02-29 | 北海道公立大学法人 札幌医科大学 | ヒストン脱アセチル化酵素阻害活性を有する物質を用いた細胞性免疫増強剤 |
| DK2099442T3 (en) | 2006-12-26 | 2015-02-16 | Pharmacyclics Inc | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| AU2007342028B2 (en) | 2006-12-29 | 2013-06-13 | Celgene Corporation | Purifiction of romidepsin |
| CA2574531C (en) * | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| WO2008090534A1 (en) * | 2007-01-26 | 2008-07-31 | Berand Limited | Methods and compositions for inhibition of excessive weight gain, reduction of inappropriate eating behaviours and inhibition of binge eating for the treatment of obesity |
| EP2170311A4 (en) * | 2007-05-16 | 2011-10-19 | Avalon Pharmaceuticals | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES |
| JP2010540426A (ja) * | 2007-09-25 | 2010-12-24 | トポターゲット ユーケー リミテッド | 特定のヒドロキサム酸化合物の合成方法 |
| CN102083428A (zh) * | 2008-03-07 | 2011-06-01 | 顶标公司 | 采用长时间连续输液Belinostat进行治疗的方法 |
| DE102008047515A1 (de) * | 2008-09-12 | 2010-03-25 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Behandlung einer demyelinisierenden Erkrankung |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| WO2011038110A2 (en) * | 2009-09-23 | 2011-03-31 | The General Hospital Corporation | Methods of treating metabolic disease |
| US20110086869A1 (en) * | 2009-09-24 | 2011-04-14 | The Trustees Of Boston University | Methods for treating viral disorders |
| CA2779497A1 (en) | 2009-10-30 | 2011-05-05 | Massachusetts Institute Of Technology | The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
| WO2011063164A2 (en) * | 2009-11-18 | 2011-05-26 | Steady Sleep Rx Co., Inc. | Sustained release cannabinoid medicaments |
| CN102802412A (zh) * | 2009-12-08 | 2012-11-28 | 海玛奎斯特医药公司 | 用于治疗红细胞病症的方法及低剂量方案 |
| US20110245154A1 (en) | 2010-03-11 | 2011-10-06 | Hemaquest Pharmaceuticals, Inc. | Methods and Compositions for Treating Viral or Virally-Induced Conditions |
| CA2804795A1 (en) | 2010-07-12 | 2012-01-19 | Nicholas Vrolijk | Romidepsin solid forms and uses thereof |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| US9018176B2 (en) * | 2010-12-02 | 2015-04-28 | Susan Perrine | Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders |
| EP2683371B1 (en) | 2011-03-09 | 2020-10-21 | Cereno Scientific AB | Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors |
| CN103917231B (zh) | 2011-09-13 | 2016-09-28 | 药品循环有限责任公司 | 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途 |
| WO2013039956A2 (en) * | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating mood disorders |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| FR3025105B1 (fr) * | 2014-09-02 | 2018-03-02 | Centre Hospitalier Universitaire Pontchaillou | Utilisation de l'acide valproique ou de ses derives dans le traitement des insuffisances en hepcidine et de leurs consequences |
| WO2017182611A1 (en) * | 2016-04-21 | 2017-10-26 | Valcuria Ab | Composition and method for pretreating cancer |
| JP2019515045A (ja) * | 2016-05-03 | 2019-06-06 | スペクトリックス セラピューティクス， エルエルシーＳｐｅｃｔｒｉｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ | 甲状腺ホルモン又はそのアナログを提供する組成物及び方法 |
| KR20200045496A (ko) * | 2017-08-29 | 2020-05-04 | 콘리그 파마 에이피에스 | 수플라타스트 토실레이트를 포함하는 조성물 |
| CN109705057B (zh) * | 2017-10-25 | 2023-05-30 | 成都先导药物开发股份有限公司 | 组蛋白去乙酰化酶抑制剂及其制备方法与用途 |
| CN108992442A (zh) * | 2018-07-12 | 2018-12-14 | 上海交通大学医学院附属瑞金医院 | Ms-275在制备促进胰岛素分泌药物中的用途 |
| CN110882250B (zh) * | 2018-09-07 | 2022-09-13 | 上海市生物医药技术研究院 | Scriptaid在制备治疗弱精症药物和试剂及器械器皿中的应用 |
| EP3976198A4 (en) | 2019-05-31 | 2023-07-19 | Viracta Subsidiary, Inc. | METHODS OF TREATMENT OF VIRAL ASSOCIATED CANCER WITH HISTONE DEACETYLASE INHIBITORS |
| CN110652506A (zh) * | 2019-11-09 | 2020-01-07 | 福建医科大学附属第一医院 | 三醋酸甘油酯在制备预防和治疗抑郁症药物中的用途 |
| CN111358777A (zh) * | 2020-02-24 | 2020-07-03 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 一种提高外周血单个核细胞线粒体功能的方法和应用 |
| US20230332155A1 (en) * | 2020-06-30 | 2023-10-19 | Korea University Research And Business Foundation | Pharmaceutical composition containing sirt7 inhibitor for preventing or treating allergic diseases |
| CN112998101A (zh) * | 2021-04-20 | 2021-06-22 | 上海舒泽生物科技研究所 | 一种人体衰老kat7基因的抑制剂固体饮料及其制备方法 |
| CN114306259B (zh) * | 2021-11-18 | 2023-06-06 | 江苏宇锐医药科技有限公司 | 一种丙戊酸钠双层缓释片及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK152744C (da) * | 1982-08-13 | 1988-10-31 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat |
| IT1215726B (it) * | 1988-01-18 | 1990-02-22 | Alfa Wassermann Spa | Formulazioni galeniche a cessione programmata. |
| IL96311A (en) * | 1989-12-01 | 1995-05-26 | Abbott Lab | Medications with delayed release |
| IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| US6287598B1 (en) * | 1993-05-28 | 2001-09-11 | Alza Corporation | Method for providing sustained antiepileptic therapy |
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| US6419960B1 (en) * | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| BR0007360A (pt) * | 1999-12-23 | 2001-08-14 | Johnson & Johnson | Composição de liberação controlada |
| EP1170008A1 (en) * | 2000-07-07 | 2002-01-09 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
| JP4632166B2 (ja) * | 2001-01-31 | 2011-02-16 | 日本ポリウレタン工業株式会社 | リグノセルロース系熱圧成形体用接着剤組成物、及びそれを用いた熱圧成形体の製造方法 |
-
2004
- 2004-04-30 EP EP04010333A patent/EP1591109B1/en not_active Expired - Lifetime
- 2004-04-30 ES ES04010333T patent/ES2308065T3/es not_active Expired - Lifetime
- 2004-04-30 PL PL04010333T patent/PL1591109T3/pl unknown
- 2004-04-30 DE DE602004014723T patent/DE602004014723D1/de not_active Expired - Lifetime
- 2004-04-30 AT AT04010333T patent/ATE399539T1/de active
- 2004-04-30 SI SI200430820T patent/SI1591109T1/sl unknown
- 2004-04-30 DK DK04010333T patent/DK1591109T3/da active
- 2004-04-30 PT PT04010333T patent/PT1591109E/pt unknown
-
2005
- 2005-05-02 WO PCT/EP2005/004739 patent/WO2005105055A1/en active Application Filing
- 2005-05-02 JP JP2007509993A patent/JP4789927B2/ja not_active Expired - Fee Related
- 2005-05-02 CN CN2005800223047A patent/CN1980647B/zh not_active Expired - Fee Related
- 2005-05-02 MX MXPA06012568A patent/MXPA06012568A/es active IP Right Grant
- 2005-05-02 US US11/587,979 patent/US20070232528A1/en not_active Abandoned
- 2005-05-02 BR BRPI0509340-6A patent/BRPI0509340A/pt not_active IP Right Cessation
- 2005-05-02 CA CA002564877A patent/CA2564877A1/en not_active Abandoned
- 2005-05-02 AU AU2005237251A patent/AU2005237251B2/en not_active Ceased
- 2005-05-02 NZ NZ550879A patent/NZ550879A/en unknown
-
2006
- 2006-10-17 ZA ZA200608714A patent/ZA200608714B/en unknown
-
2008
- 2008-08-28 CY CY20081100925T patent/CY1108301T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1591109A1 (en) | 2005-11-02 |
| MXPA06012568A (es) | 2007-04-30 |
| DK1591109T3 (da) | 2008-10-06 |
| JP2007535518A (ja) | 2007-12-06 |
| CN1980647A (zh) | 2007-06-13 |
| JP4789927B2 (ja) | 2011-10-12 |
| CN1980647B (zh) | 2010-08-18 |
| WO2005105055A1 (en) | 2005-11-10 |
| ATE399539T1 (de) | 2008-07-15 |
| NZ550879A (en) | 2010-05-28 |
| CA2564877A1 (en) | 2005-11-10 |
| EP1591109B1 (en) | 2008-07-02 |
| ES2308065T3 (es) | 2008-12-01 |
| AU2005237251A1 (en) | 2005-11-10 |
| SI1591109T1 (sl) | 2008-10-31 |
| ZA200608714B (en) | 2008-07-30 |
| BRPI0509340A (pt) | 2007-09-18 |
| AU2005237251B2 (en) | 2010-11-04 |
| PT1591109E (pt) | 2008-09-05 |
| US20070232528A1 (en) | 2007-10-04 |
| DE602004014723D1 (de) | 2008-08-14 |
| CY1108301T1 (el) | 2014-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1591109T3 (pl) | Preparat zawierający inhibitor deacetylazy histonów wykazujący dwufazowe uwalnianie” | |
| WO2002007722A3 (en) | Valproic acid and derivatives thereof as histone deacetylase inhibitors | |
| PH12015500832A1 (en) | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof | |
| DK1692097T3 (da) | Tricykliske hydroxamat- og benzamidderivater, sammensætninger og fremgangsmåder | |
| MXPA05013224A (es) | Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas. | |
| WO2009093119A3 (en) | Use of serine protease inhibitors in the treatment of skin diseases | |
| MXPA05010782A (es) | Nuevos hidroxamatos como agentees terapeuticos. | |
| GB2427405A (en) | Novel hydroxamates as therapeutic agents | |
| PL1656348T3 (pl) | Pochodne acetylenu jako inhibitory deacetylazy histonowej | |
| MXPA05008246A (es) | Inhibidores de histona desacetilasa. | |
| MY144970A (en) | Heterocyclic compounds | |
| WO2011091213A3 (en) | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | |
| MX2009011878A (es) | Compuestos antagonistas de acido ribonucleico para la modulacion de beta-catenina. | |
| EA024702B8 (ru) | Новые иммуномодуляторные и противовоспалительные соединения | |
| EP3747457A3 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| WO2004053140A3 (en) | Modulators (inhibitors/activators) of histone acetyltransferases | |
| MX2008008470A (es) | Nuevos derivados pirrolicos con actividad inhibidora de desacetilasa de histonas. | |
| MX2009005550A (es) | Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica. | |
| MX2012000541A (es) | Peptidos, polipeptidos y secuencias de acidos nucleicos terapeuticos. | |
| TN2009000448A1 (en) | Use of hdac inhibitors for the treatment of bone destruction | |
| EP4139001A4 (en) | COMBINATION THERAPY OF ARTEMISININ-RELATED COMPOUNDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF BENIGN, PREMALIGNANT AND MALIGNANT HPV-ASSOCIATED DISEASES | |
| MX2012013052A (es) | Asociacion de inhibidores de la xantina oxidasa y la instantina y su uso. | |
| WO2010062144A3 (ko) | 에타크리닉 산을 포함하는 트란스글루타미나제 관련 질환 예방 또는 치료용 조성물 및 그를 이용하는 트란스글루타미나제 관련 질환 예방 또는 치료 방법 | |
| TW200512193A (en) | Pyridinyl carbamates | |
| TH137790B (th) | 3-ซับสทิทิวเทด-4-ออกโซ-3,4-ไดไฮโดร-อิมิดาโซ[5,1-d][1,2,3-5]เททระซีน-8-คาร์บอกซิลิก แอซิด แอไมด์ และการใช้สารเหล่านี้ |